Constellation Brands (NYSE:STZ) sounded the starting gun on the recent rally in marijuana stocks when it announced its blockbuster $4 billion investment in Canopy Growth Corporation (NYSE:CGC) on Aug. 15, giving it a 38% stake in the Canadian marijuana grower. The move signaled that large, deep-pocketed companies like Constellation, which manufactures and markets beer, wine, and spirits like Corona and Svedka vodka, see big potential in pot.

Since then, marijuana stocks have gone bonkers, as Canopy, TilrayAurora CannabisCronos GroupAphria, and the ETFMG Alternative Harvest ETF have all jumped more than 50%.

MJ Chart

MJ data by YCharts.

Meanwhile, Coca-Cola (NYSE:KO) has expressed interest in cannabis-based beverages, reportedly holding talks with Aurora Cannabis, and formerly unknown stocks like New Age Beverage Corp (NASDAQ:NBEV) and India Globalization Capital have skyrocketed by multiples on their own plans to launch CBD-infused beverages. With Canada set to legalize recreational pot on Oct. 17, it's no surprise the sector is getting so much investor attention.

That's why investors were so eager to hear Constellation Brands' earnings call last week, as it marked the company's first opportunity to shed light on its massive marijuana investment and answer analysts' questions on the subject. CEO Rob Sands had plenty of tasty nuggets for investors to chew on. Here are four quotes, in particular, that stood out on the call. 

Several jars of marijuana flower with one tipped over.

Image source: Getty Images.

1. A big opportunity

Plenty of estimates have been made by research firms and others on the potential size of the cannabis market, but none of those analysts have made the kind of bet that Constellation did on the space. Here's what Sands had to say about the opportunity in cannabis:

With our focus on continuous growth, we've recognized the significant opportunity that the emerging cannabis space presents as potentially one of the significant global growth opportunities of the next decade... This [the $4 billion investment] will be the largest investment to date in the cannabis space, a market which is expected to reach more than $200 billion in retail sales globally within the next 15 years, and one that is opening up much more rapidly than originally anticipated.

If marijuana legalization progresses as advocates and investors hope it will, $200 billion in retail sales by 2033 doesn't seem unreasonable. By comparison, global sales of alcohol -- which some see marijuana as a substitute for or a complement to -- is projected to grow from annual global sales of $1.35 trillion in 2015 to $1.6 trillion in 2022, according to Allied Market Research. By comparison, the global tobacco market is estimated to generate $760 billion in annual sales, excluding China. Colorado alone saw $1.5 billion in marijuana sales last year, which would translate to $100 billion across North America if consumption were similar and it was legalized federally in the U.S.

2. Why Canopy?

Not surprisingly, Canopy Growth stock has skyrocketed since Constellation made its initial investment last year, as shares are up nearly 400% from a year ago. CEO Sands took time in the earnings call to explain why the company had so much confidence in Canopy Growth and why it sees it as the market leader. Here's what he had to say:

Canopy Growth has the largest legal cannabis production footprint in the world and in Canada, and they are the only producer currently participating in all Canadian provinces. They also have been awarded approximately 35% of the supply contracts announced throughout all Canadian provinces to date that are dedicated to recreational cannabis, a market that will become legal in Canada later this month. Going forward, we will be working exclusively with Canopy, as we believe that having a single platform to address all markets and formats globally is essential to winning in this space.

Sands went on to explain that those supply contracts should give Canopy billions in annual revenue once recreational pot becomes legal in Canada on Oct. 17. Projections for first-year sales are between $5 billion and $7 billion in revenue for the first year, which should give Canopy around $2 billion in revenue, considering it has about one-third of the supply contracts.

3. No evidence of alcohol cannibalization

One concern about marijuana legalization, especially for alcohol companies, has been cannibalization. Investors and others have feared that legal pot would cause alcohol consumption to decline as consumers would have another recreational drug to choose from. However, Constellation hasn't seen any evidence to indicate that legal marijuana is stealing sales from alcohol. Here's Sands on the matter:

We see no evidence whatsoever, especially in the United States in the legal states, of alcohol cannibalization. So, I'd say as we sit here right now and we think about the cannabis business and our position in the cannabis business, it's probably going to be close to 100% incremental for us, talking about incrementality. So, this conversation comes up a lot. Two things, OK? Number one, is it a defensive move? The answer is no. We're not playing defense, we're playing offense. This is an offensive move, period.

That conclusion should reassure alcohol investors, but it's also good news for marijuana investors, as it means that alcohol companies could give up or at least mitigate their historical opposition to national legalization of pot, as they have seen it as a threat to their business for a long time. Additionally, investments by Constellation and Molson Coors in marijuana companies indicate that beer makers and others see potential in pot.

4. Constellation is well-positioned 

Towards the end of the earnings call, Sands once again touted Constellation's strong position in the evolving marijuana industry and its investment in Canopy, as well as expertise in marketing, distribution, and beverages. The stock could be a hidden winner in the marijuana boom after the market pooh-poohed its tie-up with Canopy, sending the stock lower. This is how Sands sees it developing:

So, we think that we're by far the best company in the world, or in the best position in the world of any company to capitalize on what is absolutely without a doubt going to be a huge market over the next 10 years. Hundreds of billions of dollars. So, we're addressing our position on every front, meaning that we need to be a key player in the development of the science. That's really important. Branding, we've got top people and top agencies and firms working on branding, because like all businesses of this nature and consumer products, branding is gonna be the key to success in the future.

The marijuana market is evolving faster than most expected, and Constellation's partnership with Canopy has quickly gone from a joint venture to test beverages to a multibillion-dollar deal that gives Constellation the opportunity to take majority ownership of the company through warrants. 

With Sands' company now the biggest marijuana investor in the world, individual marijuana investors will want to pay close attention to his assessment of the market. Stay tuned, especially with Canadian legalization right around the corner.

Jeremy Bowman owns shares of ETFMG Alternative Harvest ETF. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.